Tags

Type your tag names separated by a space and hit enter

Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. Parkinson Study Group.
JAMA. 1997 Jul 09; 278(2):125-30.JAMA

Abstract

CONTEXT

Monotherapy with dopamine agonists may be useful in early Parkinson disease.

OBJECTIVE

To evaluate dose-response relationships for tolerability, safety, and efficacy of the synthetic dopamine agonist pramipexole.

DESIGN

Multicenter, multidosage, parallel-group, double-blind, placebo-controlled, randomized clinical trial.

SETTING

University or academically based movement disorder clinics.

PATIENTS

A total of 264 patients with early Parkinson disease (PD) who were not requiring or receiving levodopa or other dopamine agonists were enrolled.

INTERVENTION

Subjects were randomized to 1 of 5 treatment groups: pramipexole doses of 1.5 mg/d, 3.0 mg/d, 4.5 mg/d, and 6.0 mg/d, or matching placebo. A 6-week dosage escalation period was followed by a 4-week maintenance period and a 1-week period during which active treatment was withdrawn.

MAIN OUTCOME MEASURES

The primary measure of tolerability was the proportion of subjects completing the study on the assigned treatment. The primary measure of efficacy was the change from baseline to 10 weeks in the total score on the Unified Parkinson's Disease Rating Scale (UPDRS).

RESULTS

Pramipexole was generally safe and well tolerated in this 10-week study. The proportion of subjects completing the study on the originally assigned dosage was 98% for placebo and 81% for the 1.5-mg/d, 92% for the 3.0-mg/d, 78% for the 4.5-mg/d, and 67% for the 6.0-mg/d treatment groups. There was a trend toward increased frequency of adverse experiences, particularly somnolence, in the 6.0-mg/d group. After 10 weeks of treatment, pramipexole-treated subjects showed a 20% improvement in total UPDRS scores, with mean improvements in scores ranging from 5.9 to 7.0 units among active treatment groups, compared with 0.9 units for the placebo group (P<.005 for each comparison with placebo). There was also evidence that the treatment effects were more pronounced in subjects with worse UPDRS scores at baseline.

CONCLUSIONS

Pramipexole is safe and effective as short-term monotherapy in patients with early PD who are not receiving levodopa. Further study is warranted to determine the long-term impact of pramipexole on the progression of disability in PD and its value in comparison with levodopa therapy and other dopamine agonists.

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

9214527

Citation

"Safety and Efficacy of Pramipexole in Early Parkinson Disease. a Randomized Dose-ranging Study. Parkinson Study Group." JAMA, vol. 278, no. 2, 1997, pp. 125-30.
Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. Parkinson Study Group. JAMA. 1997;278(2):125-30.
(1997). Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. Parkinson Study Group. JAMA, 278(2), 125-30.
Safety and Efficacy of Pramipexole in Early Parkinson Disease. a Randomized Dose-ranging Study. Parkinson Study Group. JAMA. 1997 Jul 9;278(2):125-30. PubMed PMID: 9214527.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. Parkinson Study Group. PY - 1997/7/9/pubmed PY - 1997/7/9/medline PY - 1997/7/9/entrez SP - 125 EP - 30 JF - JAMA JO - JAMA VL - 278 IS - 2 N2 - CONTEXT: Monotherapy with dopamine agonists may be useful in early Parkinson disease. OBJECTIVE: To evaluate dose-response relationships for tolerability, safety, and efficacy of the synthetic dopamine agonist pramipexole. DESIGN: Multicenter, multidosage, parallel-group, double-blind, placebo-controlled, randomized clinical trial. SETTING: University or academically based movement disorder clinics. PATIENTS: A total of 264 patients with early Parkinson disease (PD) who were not requiring or receiving levodopa or other dopamine agonists were enrolled. INTERVENTION: Subjects were randomized to 1 of 5 treatment groups: pramipexole doses of 1.5 mg/d, 3.0 mg/d, 4.5 mg/d, and 6.0 mg/d, or matching placebo. A 6-week dosage escalation period was followed by a 4-week maintenance period and a 1-week period during which active treatment was withdrawn. MAIN OUTCOME MEASURES: The primary measure of tolerability was the proportion of subjects completing the study on the assigned treatment. The primary measure of efficacy was the change from baseline to 10 weeks in the total score on the Unified Parkinson's Disease Rating Scale (UPDRS). RESULTS: Pramipexole was generally safe and well tolerated in this 10-week study. The proportion of subjects completing the study on the originally assigned dosage was 98% for placebo and 81% for the 1.5-mg/d, 92% for the 3.0-mg/d, 78% for the 4.5-mg/d, and 67% for the 6.0-mg/d treatment groups. There was a trend toward increased frequency of adverse experiences, particularly somnolence, in the 6.0-mg/d group. After 10 weeks of treatment, pramipexole-treated subjects showed a 20% improvement in total UPDRS scores, with mean improvements in scores ranging from 5.9 to 7.0 units among active treatment groups, compared with 0.9 units for the placebo group (P<.005 for each comparison with placebo). There was also evidence that the treatment effects were more pronounced in subjects with worse UPDRS scores at baseline. CONCLUSIONS: Pramipexole is safe and effective as short-term monotherapy in patients with early PD who are not receiving levodopa. Further study is warranted to determine the long-term impact of pramipexole on the progression of disability in PD and its value in comparison with levodopa therapy and other dopamine agonists. SN - 0098-7484 UR - https://www.unboundmedicine.com/medline/citation/9214527/Safety_and_efficacy_of_pramipexole_in_early_Parkinson_disease__A_randomized_dose_ranging_study__Parkinson_Study_Group_ L2 - https://jamanetwork.com/journals/jama/fullarticle/vol/278/pg/125 DB - PRIME DP - Unbound Medicine ER -